Anti-antibiotics

July 22, 2013
Two scenarios of antimicrobial peptide action: (top) an antimicrobial peptide binds to microbial membranes and forms membrane-disrupting helical structures or (bottom) when challenged by an anti-antimicrobial peptide it forms a biologically inert helical complex

Antimicrobial peptides are natural antibiotics found in all multicellular organisms. These molecules are viewed as potential drug candidates in the post-antibiotic era because widespread microbial resistance against them has yet to emerge.

The use of these peptides in medicine may trigger the development of antimicrobial resistance in a fashion similar to that currently occurring with more conventional antibiotics such as methicillin and vancomycin. However, the mechanism of action of , which target and rapidly destroy bacterial membranes, lends credibility to the view that this is unlikely to happen. To acquire resistance against such formidable agents, microorganisms would need to re-build their genetic apparatus, which is an extremely high price to pay.

In a recent study, a research team comprising scientists from NPL, University of Bristol, University of Edinburgh, University of Oxford and IBM explored the effect of designed to be antagonistic towards antimicrobial peptides. The research showed that these 'anti-antimicrobial' sequences interact with the antimicrobial peptides to form inert molecular complexes, known as helical oligomers.

The team then studied the structural and biological properties of these inert assemblies in biologically relevant environments, using a combination of spectroscopy, microscopy, bioassays and . The findings, reported in the Journal of Biological Chemistry, suggest that antagonistic sequences secreted by bacterial cells or expressed on their surfaces may cause efficient anti-antimicrobial responses. Although this remains to be shown in nature, this research offers a molecular rationale for these responses with potential implications for antimicrobial resistance.

Lloyd Ryan, an NPL research scientist who worked on the project, said:

"It is widely believed that antimicrobial peptides are powerful antibiotics that can overcome the we see nowadays in clinics. However, for us it was important to understand if a relatively simple mechanism of resistance is plausible against antimicrobial peptides before they are considered for use on an industrial scale."

Explore further: Do it like the immune system: novel antimicrobials

More information: www.jbc.org/content/288/28/20162.long

Related Stories

Do it like the immune system: novel antimicrobials

August 30, 2012

Microbial infections are becoming unbeatable due to progressive mutations that lead to antimicrobial drug resistance. European scientists exploited the characteristics of novel antimicrobial compounds that mimic the dual ...

Antimicrobial resistance in Vietnam

May 7, 2013

Heiman Wertheim and Arjun Chandna from Oxford University and colleagues describe the launch and impact of VINARES, an initiative to strengthen antimicrobial stewardship in Viet Nam, which may be instructive for other countries ...

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.